Scarica l'app Stockscreener
0.283
1.01%
-0.0029
Dopo l'orario di chiusura:
.28
-0.003
-1.06%
Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.26, Down by -5.05 - DWinneX
Let’s Jump Into The Geron Corp (NASDAQ: GERN) Stock Forecast - Marketing Sentinel
Bausch + Lomb Corp (NYSE:BLCO)’s 12-Month Price Target Is Now Set At 23. - Marketing Sentinel
B. Riley Financial Inc (NASDAQ:RILY) Shares Dropped -2.22% In A Week. Can It Continue Rising? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Could Really Rise To 4 In 12 Months, According To Analysts. - Marketing Sentinel
Is Live Oak Bancshares Inc (NYSE:LOB) A Better Buy Than Others After A -32.27% Fall In This Year? - Marketing Sentinel
Eventbrite Inc (NYSE:EB) Declines -81.18% In 2025; Are Investors Attracted By Its $2.10 Price? - Marketing Sentinel
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
TransCode Therapeutics Inc: Weathering Stock Market Storms with 8.59M Market Cap - investchronicle.com
Charting the Course: Tempest Therapeutics Inc’s TPST Stock Prospects - investchronicle.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics Plc ADR (ADAP)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater
SM Energy Co (SM): A Technical Analysis - The News Heater
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile
Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News
Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex
Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India
Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa
Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):